Methods of immunotherapy
AssigneeThe Council of the Queensland Institute of Medical Research
InventorsRajiv KHANNA, Corey Smith
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions related to the selection T cells and/or subjects for adoptive immunotherapy based on the expression of one or more biomarkers.
Claims46
1-85. (canceled)
A method of selecting a sample comprising T cells for adoptive immunotherapy or for inclusion in a cell bank, the method comprising determining the expression of IFNg, CD107a, IL-2, TNF, granzyme B, granzyme K, perforin, or any combination thereof by lymphocytes in the sample and selecting the sample for adoptive immunotherapy if at least a threshold level of the lymphocytes in the sample express any one of IFNg, CD107a, IL-2, TNF, granzyme B, granzyme K, perforin, or a combination thereof.
(canceled)
(canceled)
A method of selecting a sample comprising T cells for ex vivo expansion, comprising:
- (a) inducing proliferation in T cells from a portion of the sample,
- (b) determining the expression of IFNg, CD107a, IL-2, TNF, granzyme B, granzyme K, perforin, or any combination thereof by the lymphocytes in the portion of the sample;
- and
- (c) selecting the sample for expansion if at least a threshold level of the lymphocytes express IFNg, CD107a, IL-2, TNF, granzyme B, granzyme K, perforin, or a combination thereof.
(canceled)
94-108. (canceled)
110-125. (canceled)
127-299. (canceled)
301-317. (canceled)
320-322. (canceled)
A cell bank of samples comprising T cells, wherein the cell bank is enriched for samples in which at least a threshold level of lymphocytes in the sample express a biomarker, wherein the threshold level of lymphocytes expressing the biomarker is:
- (a) at least 1% of lymphocytes in the sample express IFNg;
- (b) at least 1% of the lymphocytes in the sample express CD107a;
- (c) at least 1% of the lymphocytes in the sample express IL-2;
- (d) at least 1% of the lymphocytes in the sample express TNF;
- (e) at least 5% of lymphocytes in the sample express granzyme B;
- (f) at least 3% of the lymphocytes in the sample express granzyme K;
- (h) at least 2% of the lymphocytes in the sample express perforin;
- (i) at least 20% of the lymphocytes in the sample express CD8;
- (j) at least 10% of the lymphocytes in the sample express CD4;
- (k) at least 5% of the lymphocytes in the sample express PD-1;
- (l) at least 8% of the lymphocytes in the sample express TIM-3;
- (m) at least 3% of the lymphocytes in the sample express LAG-3;
- or
- (n) at least 8% of the lymphocytes in the sample express CTLA-4.
337-344. (canceled)
346-348. (canceled)
A method of selecting a subject for autologous adoptive immunotherapy, comprising:
- a) inducing proliferation of the T cells obtained from the subject,
- b) determining the expression of IFNg by the T cells, and
- c) selecting the subject for autologous adoptive immunotherapy if at least a threshold level of the lymphocytes express IFNg.
350-402. (canceled)
(canceled)
Dependencies are inferred from the claim text.